The absence of the active form of FGF23 due to an inactivating mutation in the FGF23 or lack of FGF23 effect due to a mutation in the Klotho gene can cause hyperphosphatemia, hyperostosis and/or tumoral calcinosis [9]. This evidence concerns the gene FGF23 and hyperostosis.